Black Diamond Therapeutics Inc at Jefferies Healthcare Conference Transcript
It's my pleasure to introduce David Epstein, CEO of Black Diamond Therapeutics (inaudible - microphone inaccessible).
All right. Well, thank you. Welcome everybody. Thank you for attending this talk. Happy to be here representing Black Diamond Therapeutics. Just to remind you, this presentation contains forward-looking statements, particularly with regard to our clinical programs, use of proceeds, and our research efforts.
I want to take a moment just to talk about how important 2023 is for the company. This is really going to be a great year for what Black Diamond has set out to do. This is a year where we're going to update, in the second half of 2023, the progress on our BDTX-1535 clinical program. That clinical data will include a summary of our Phase 1 dose escalation study.
We also have initiated our clinical program, BDTX-4933. It's our MasterKey inhibitor targeting RAF and RAS mutations. We recently announced the progression of an FGFR
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |